A monoclonal antibody IMab-1 specifically recognizes IDH1, the most common glioma-derived mutation

IDH1 (isocitrate dehydrogenase 1) mutations have been identified as early and frequent genetic alterations in astrocytomas, oligodendrogliomas, and oligoastrocytomas as well as secondary glioblastomas. In contrast, primary glioblastomas very rarely contain IDH1 mutations, although primary and secondary glioblastomas are histologically indistinguishable. The IDH1 mutations are remarkably specific to a single codon in the conserved and functionally important Arg132 in IDH1. In gliomas, the most frequent IDH1 mutations (>90%) were G395A (R132H). In this study, we immunized mice with R132H-containing IDH1 (IDH1^R132H) peptide. After cell fusion using Sendai virus envelope, the monoclonal antibodies (mAbs), which specifically reacted with IDH1^R132H, were screened in ELISA. One of the mAbs, IMab-1 reacted with the IDH1^R132H peptide, but not with wild type IDH1 (IDH1^wt) peptide in ELISA. In Western-blot analysis, IMab-1 reacted with only the IDH1^R132H protein, not IDH1^wt protein or the other IDH1 mutants, indicating that IMab-1 is IDH1^R132H-specific. Furthermore, IMab-1 specifically stained the IDH1^R132H-expressing cells in astrocytomas in immunohistochemistry, whereas it did not react with IDH1^R132H-negative primary glioblastoma sections. In conclusion, we established an anti-IDH1^R132H-specific monoclonal antibody IMab-1, which should be significantly useful for diagnosis and biological evaluation of mutation-bearing gliomas.